A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

504

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

November 15, 2022

Study Completion Date

May 12, 2023

Conditions

Ankylosing Spondylitis

Interventions

DRUG

SHR0302

SHR0302, oral, once daily

DRUG

SHR0302 placebo

SHR0302 placebo, oral, once daily

Trial Locations (1)

Zhanguo Li, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04481139 - A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter